Dimension Therapeutics to Participate in Canaccord Genuity 2016 Rare Disease Biopharma Day and SunTrust Robinson Humphrey 2016 Orphan Drug Day
January 27, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
Dimension Therapeutics Announces Initiation of Phase 1/2 Study for DTX101 for the Treatment of Hemophilia B
January 07, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
Dimension Therapeutics Announces Orphan Drug Designation of DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
January 06, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2015 Financial Results
December 04, 2015 16:15 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Dec. 4, 2015 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
Dimension Therapeutics Announces Expansion of Internal Research and Process Development Capabilities
November 03, 2015 16:30 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
Dimension Therapeutics Announces Pricing of Initial Public Offering
October 21, 2015 20:51 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a leading gene therapy company advancing novel, liver-directed treatments for diverse...